avatar

Exciting times at Oculus

by Jim Schutz, Oculus CEO

The team has had a busy Spring:

Posted in Oculus Future by Jim Schutz on May 6th, 2013
No Comments »

 
avatar

Transitions

By Jim Schutz, Oculus CEO

Our founder & CEO, Hoji Alimi, has for years generously asked for my advice to help create long-term shareholder value at Oculus. Hoji and the board recently asked me to stop “with the free advice” and step up as the new CEO—an opportunity, by the way, which I treasure as once-in-a-lifetime chance.

During the first hundred days of this transition, my hope is to report back to you—our shareholders—regularly, via this column.  Over the next few months, please stay tuned as we further detail our strategies, our wins, as well as the challenges ahead.

Read More »

Posted in Oculus Future by Jim Schutz on February 1st, 2013
No Comments »

 
avatar

Oculus on the Right Track

By Hoji Alimi
Oculus Founder and CEO

In the past few weeks, I’ve been busy communicating with our shareholders regarding two most positive events.  The first was our first quarter fiscal year 2013 earning report issued on August 2nd in which we reported record revenues of $4.1 million for the quarter (significantly surpassing our guidance of greater than $3.3 million) and a 41% increase over the same quarter of fiscal year 2012—leaving us just $22,000 shy of EBITDAS break even.  Exciting quarterly growth, especially in the United States where we experienced a 141% revenue increase over the previous year’s quarter, primarily due to the introduction of new Microcyn-based dermatology products by our U.S. partners.   It is reassuring to see that our global partnering strategy has put us squarely on the track headed towards profitability.

Read More »

Posted in Oculus Future by Hoji Alimi on August 14th, 2012
No Comments »

 
avatar

On the Right Track: New Acne Drug Agreement with AmDerma

Hoji Alimi
Oculus Founder and CEO

I’m proud we’ve created a company that is commercializing compounds which can reduce the overall use of antibiotics in multiple markets.  This past week we announced a licensing agreement for use of the Microcyn® Technology as an acne drug (and other dermatological indications) in the United States with our partner AmDerma.  Once commercialized, the Microcyn-based acne drug will provide Oculus with double-digit royalties in a relatively large addressable market.

Read More »

Posted in Dermatology by Hoji Alimi on June 29th, 2012
No Comments »

 
avatar

Microcyn Technology in the Treatment of Acne

By Jim Schutz, Oculus COO

During our quarterly earnings calls, we enjoy taking a few extra minutes to describe a patient story or two.  We’re often advised by Wall Street experts that big pharma companies use their earnings calls just to highlight their financials—and, because we all follow big pharma, we should as well.

We respectfully disagree.  We look forward to hearing from our patients and as Hoji constantly reminds us, companies like Apple are dominant in multiple markets because of their zealous commitment to listening to their customers.  So bear with me as I describe an interesting new patient story.  This one is from Mexico and describes terrific results using our new acne medication, GramaDerm. Read More »

Posted in Dermatology, Microcyn Technology, New Microcyn Products, Oculus Future, Patient Success Stories by Jim Schutz on March 1st, 2011
No Comments »

 
avatar

Oculus’ Strategic Shift

By Jim Schutz, COO

In late 2008, as the economy was faltering and cash at Oculus was running thin, our CEO, Hoji Alimi, CFO Bob Miller and I locked ourselves into a window-less office at our headquarters in Northern California, turned off our phones, closed our laptops and stood before a white board to chart our course.  Our stock price was at an all-time low, our access to cash to fund operations was non-existent (across all industries as you may recall) and we had to right the ship. Read More »

Posted in Oculus Future by Jim Schutz on December 1st, 2010
1 Comment »

 
avatar

Upcoming Catalysts

By Jim Schutz
Oculus COO

Last week, we released our earnings for the quarter ending June 30, 2010 and have received lots of feedback from our shareholders and analysts.  Several highlights:

  • We hit our numbers for the 6th quarter in a row on both revenue and operating expenses,
  • Our cash position is healthy, and
  • We’ve converted from a one compound company into a commercial stage enterprise with more than 20 products in the market, just in the US.

Read More »

Posted in Oculus Future by Jim Schutz on August 17th, 2010
No Comments »

 
avatar

A Tale of Two Cities

By Dan McFadden
Oculus Director of Investor Relations

As director of investor and public relations at Oculus, I have one of the best jobs in the company.  Since I joined the Oculus team in January 2004, I’ve had the pleasure of meeting with hundreds of doctors/patients from around the globe (in my efforts to document through video, photos and written chronicle, their experiences) that have been successfully treated with the Microcyn Technology.  It’s truly an uplifting experience when you can see the real-world impact of saving patient lives.

Read More »

Posted in Patient Success Stories by Dan McFadden on July 1st, 2010
No Comments »

 
avatar

Success Stories from the Field

By Jim Schutz
Oculus COO

I hope this message finds you all well.

All is well at Oculus after a solid Q4 earnings call in early June.  In anticipation of our earnings calls, we typically prepare several days in advance to ensure our message is clear and concise.  Our message on this call was clear-cut: Revenue was up in the United States, Mexico, China, India and the Middle East with 65%+ growth and expenses were flat across the board.

Read More »

Posted in Patient Success Stories by Jim Schutz on June 28th, 2010
No Comments »

 
avatar

What a Difference a Year Makes!

As part of my responsibilities as the CEO of Oculus, I attend various financial conferences where we present the Oculus story to investment funds or institutions.  Just this week, we attended an annual growth stock conference in Southern California.  We presented to a room full of investors (you can view/hear the presentation by visiting http://www.wsw.com/webcast/roth23/ocls/ ) and then followed with a series of one-on-one meetings for 30-minutes or so with individual fund managers.

Read More »

Posted in Oculus Future by Hoji Alimi on March 25th, 2010
No Comments »